Imidazolidine derivatives, their preparation and their use

Details Imidazolidine derivatives, their preparation and their use Imidazolidine derivatives, their preparation and their use

2005-11-08

2005-11-08

Shameem, Golam M M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S319500

Reexamination Certificate

active

06962937

ABSTRACT:
The present invention relates to novel imidazolidine derivatives of the formula I,in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. The invention furthermore relates to processes for preparing the compounds of the formula I, to their use and to pharmaceutical preparations which comprise compounds of the formula I.

REFERENCES:
patent: 5389614 (1995-02-01), Koenig et al.
patent: 5397796 (1995-03-01), Zoller et al.
patent: 5424293 (1995-06-01), Zoller et al.
patent: 5554594 (1996-09-01), Zoller et al.
patent: 5658935 (1997-08-01), Klingler et al.
patent: 5686421 (1997-11-01), Koenig et al.
patent: 5939556 (1999-08-01), Zoller et al.
patent: 5981492 (1999-11-01), Zoller et al.
patent: 5998447 (1999-12-01), Stilz et al.
patent: 6034238 (2000-03-01), Wehner et al.
patent: 6218415 (2001-04-01), Wehner et al.
patent: 6331552 (2001-12-01), Wehner et al.
patent: 6423712 (2002-07-01), Wehner et al.
patent: 235 866 (1986-05-01), None
patent: DD 235 866 (1986-05-01), None
patent: 0 796 855 (1997-03-01), None
patent: 0 842 943 (1997-11-01), None
patent: 0 842 944 (1997-11-01), None
patent: 0 842 945 (1997-11-01), None
patent: 0 903 353 (1998-09-01), None
patent: 0 905 139 (1998-09-01), None
patent: 0 918 059 (1998-11-01), None
patent: WO 93/13798 (1993-07-01), None
patent: WO 93/15764 (1993-08-01), None
patent: WO 93/18057 (1993-09-01), None
patent: WO 94/15958 (1994-07-01), None
patent: WO 94/16094 (1994-07-01), None
patent: WO 94/17828 (1994-08-01), None
patent: WO 95/14008 (1995-05-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 95/19790 (1995-07-01), None
patent: WO 96/00581 (1996-01-01), None
patent: WO 96/06108 (1996-02-01), None
patent: WO 96/20216 (1996-07-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/33976 (1996-10-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 98/04247 (1998-02-01), None
patent: WO 98/04913 (1998-02-01), None
patent: WO 98/42656 (1998-10-01), None
patent: WO 99/23063 (1999-05-01), None
patent: WO 99/24398 (1999-05-01), None
patent: WO 99/54321 (1999-10-01), None
patent: WO 99/60015 (1999-11-01), None
patent: WO 00/00477 (2000-01-01), None
patent: WO 00/02903 (2000-01-01), None
patent: WO 00/69831 (2000-11-01), None
Abraham, William M. et al., “α4- Integrins Mediate Antigen-induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep”,J. Clin. Invest., vol. 93, Feb. 1994, 776-787, The American Society for Clinical Investigation, Inc., Ann Arbor MI USA.
Adams, David H. et al., “Experimental Graft Arteriosclerosis,”,Transplantation, vol. 56, 794-799, No. 4, Oct., 1993, Lippincott Williams & Wilkins, Baltimore MD USA.
Albelda, Steven M. et al., “Molecular and Cellular Properties of PECAM-1 (endoCAM/CD31): A Novel Vascular Cell-Cell Adhesion Molecule”,The Journal of Cell Biology, vol. 114, No. 5, Sep. 1991, 1059-1068, The Rockefeller University Press, New York NY USA.
Barbadillo, Carmen et al., “Anti-integrin immunotherapy in rheumatoid arthtiris: protective effect of anti-α4 antibody in adjuvant arthritis”,Springer Semin Immunopathol., (1995) 16:427-436, Springer-Verlag, New York NY USA.
Bergelson, J.M. et al., “Do integrins use a ‘MIDAS touch’ to grasp as Asp?”,Current Biology, 1995, vol. 5, No. 6, 615-617, Cell Press, Cambridge MA USA.
Bergeron, Raymond J. et al., “Total Synthesis of (±)-15-Deoxyspergualin”,J. Org. Chem., 1987, 52, 1700-1703, American Chemical Society. Washington DC USA.
Borne, R. F. et al., “Conformational Analogues of Antihypertensive Agents Related to Guanethidine”,Journal of Medicinal Chemistry, 1977, vol. 20, No. 6, pp. 771-776, American Chemical Society, Columbus OH USA.
Büllesback, E.E., “Schutzgruppen in der Peptidsynthese (Teil 2): Mehrfunktionelle Aminosäuren—zur Abspaltung—Perspektiven der Schutzgruppentechnik”,KONTAKTE 1/80, Torino IT.
Bundgaard, Hans, “Novel chemical approaches in prodrug design”,Drugs of the Future, 1991, 16(5), 443-458, Prous Science, Philadelphia PA USA.
Cronstein, Bruce N. et al., “The adhesion molecules of inflammation”,Arthritis and Rheumatism, vol. 36, No. 2, Feb. 1993, pp. 147-157, American College of Rheumatology, Atlanta GA USA.
Damle, Nitin K. et al., “Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes”,Proc. Natl. Acad. Sci. USA, vol. 88, pp. 6403-6407, Aug. 1991, National Academy of Sciences, Washington DC USA.
Davies, Stephen G. et al., “Asymmetric Synthesis of R-β-amino Butanoic Acid and S-β-tyrosine: Homochiral Lithium Amide Equivalents for Michael Additions to α,β-Unsaturated Esters”,Tetrahedron:Asymmetry, vol. 2, No. 3, pp. 183-188, 1991, Elsevier Sciences Ltd., London UK.
Davies, Stephen G. et al., “Asymmetric Synthesis of anti-α-Alkyl-β-amino Acids”,J. Chem. Soc. Perkin Trans, 1, 1994, pp. 1129-1139, Royal Society of Chemistry, London UK.
Dinther-Janssen, Anna C. H. M. Van et al., “The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium1”,The Journal of Immunology, vol. 147, 4207-4210, No. 12, Dec. 5, 1991, The American Association of Immunologists, Bethesda, MD, USA.
Elices, Mariano J., “The integrin α4β1 (VLA-4) as a therapeutic target”,Cell Adhesion and Human Disease, 1995, Wiley, Chichester (Ciba Foundation Symposium 189) p. 79-90, John Wiley & Sons, Inc., Hoboken NJ USA.
Elices, M. J. et al., “The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vivo”,Clinical and Experimental Rheumatology, 11, (Suppl. 8): S77-S80, 1993, Pisa IT.
Elices, Mariano J. et al., “Expression and Functional Significance of alternatively spliced CS1 fibronectin in rheumatoid arthritis microvasculature”,J. Clin. Invest., vol. 93, Jan. 1994, 405-416, The American Society for Clinical Investigation, Inc., Ann Arbor MI USA.
Elices, Mariano J. et al., “VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site”,Cell, vol. 60, 577-584, Feb. 23, 1990, Cell Press, Cambridge MA USA.
Fehrentz, Jean-Alain, “An Efficient Synthesis of Optically Active α-(t-Butoxycarbonylamino)-aldehydes from α-Amino Acids”,Synthesis, Aug. 1993, pp. 676-678.
Fleisher, David et al., “Improved oral drug delivery: solubility limitations overcome by the use of prodrugs”,Advanced Drug Delivery Reviews, 19 (1996), 115-130, Elsevier Science B.V., Amsterdam, The Netherlands.
Foster, Carolyn A. Ph.D., “VCAM-1/α4-integrin pathway: Therapeutic target for allergic inflammatory disorders”,J. Allergy Clin. Immunol., vol. 98, No. 6, Part 2, S270-S277, Mosby-Year Book, Inc, Oxford, UK.
Freedman, Arnold S., “Follicular Non-Hodgkin's lymphoma cell adhesion to normal germinal centers and neoplastic follicles involves very late antigen-r and vascular cell adhesion molecule-1”,BLOOD, vol. 79, No. 1 (Jan. 1), 1992: pp. 206-212, Birmingham, AL USA.
Hafner, L.S. et al., “Preparation of 2-Imino- and 2-Nitrimon-1,3-diazacycloalkanes”,J. Org. Chem., vol. 24, (1959), pp. 1157-

Affiliated with

Also associated with

Rating

Imidazolidine derivatives, their preparation and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazolidine derivatives, their preparation and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidine derivatives, their preparation and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3469800